Regeneron Pharmaceuticals Inc (REGN)
$798.59-1.13%previous session's close (28 Aug 2026) — awaiting today's first price update
Spriggl Score: Good— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Dupixent growth of 33% and new gene therapy approval drive value, but the 36% rally and legal overhang cap upside potential.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and …
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- $85.3B
Recent dividends
- 18 Aug 2026$0.94
- 20 May 2026$0.94
- 20 Feb 2026$0.94
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Regeneron Pharmaceuticals Inc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free